NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, Forecast & News

GW Pharmaceuticals PLC-'s stock was trading at $86.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GWPH stock has decreased by 2.7% and is now trading at $84.52. View which stocks have been mosted impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) announced its earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.32. The biopharmaceutical company earned $109.10 million during the quarter, compared to the consensus estimate of $80.92 million. GW Pharmaceuticals PLC- had a negative return on equity of 16.12% and a negative net margin of 2.90%. The firm's revenue for the quarter was up 1528.4% compared to the same quarter last year. During the same period last year, the business earned ($0.20) EPS. View GW Pharmaceuticals PLC-'s earnings history.

13 analysts have issued 12 month target prices for GW Pharmaceuticals PLC-'s stock. Their forecasts range from $134.00 to $260.00. On average, they expect GW Pharmaceuticals PLC-'s stock price to reach $198.42 in the next year. This suggests a possible upside of 134.8% from the stock's current price. View analysts' price targets for GW Pharmaceuticals PLC-.

Headlines about GWPH stock have been trending very negative on Friday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GW Pharmaceuticals PLC- earned a news impact score of -3.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutGW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- saw a decline in short interest in February. As of February 28th, there was short interest totaling 5,250,000 shares, a decline of 6.9% from the February 13th total of 5,640,000 shares. Based on an average daily volume of 609,800 shares, the short-interest ratio is currently 8.6 days. Currently, 17.1% of the shares of the stock are short sold. View GW Pharmaceuticals PLC-'s Current Options Chain.

Some companies that are related to GW Pharmaceuticals PLC- include Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Elanco Animal Health (ELAN), Mylan (MYL), Sarepta Therapeutics (SRPT), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ) and Bausch Health Companies (BHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Aurora Cannabis (ACB), Cronos Group (CRON), Tesla (TSLA), Zynerba Pharmaceuticals (ZYNE) and Intel (INTC).

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GWPH stock can currently be purchased for approximately $84.52.

GW Pharmaceuticals PLC- has a market capitalization of $2.61 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe. View additional information about GW Pharmaceuticals PLC-.

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/.

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]